Get the Stockscreener App
5.27
9.56%
0.46
After Hours:
5.38
0.11
+2.09%
Neonc Technologies Holdings Inc stock is traded at $5.27, with a volume of 373.25K.
It is up +9.56% in the last 24 hours and down -1.31% over the past month.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
See More
Previous Close:
$4.81
Open:
$4.88
24h Volume:
373.25K
Relative Volume:
4.45
Market Cap:
$136.67M
Revenue:
$40,000
Net Income/Loss:
$-38.64M
P/E Ratio:
-2.862
EPS:
-1.8414
Net Cash Flow:
$-22.21M
1W Performance:
+17.11%
1M Performance:
-1.31%
6M Performance:
-24.93%
1Y Performance:
+10.71%
1-Day Range:
$4.8225
$5.35
1-Week Range:
$4.30
$5.6646
52-Week Range:
$3.20
$12.99
Neonc Technologies Holdings Inc Stock (NTHI) Company Profile
Name
Neonc Technologies Holdings Inc
Sector
Industry
Phone
310 663 7831
Address
23975 PARK SORRENTO, CALABASAS
Compare NTHI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTHI
Neonc Technologies Holdings Inc
|
5.27 | 124.74M | 40,000 | -38.64M | -22.21M | -1.8414 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 116.49B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 55.49B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 33.54B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neonc Technologies Holdings Inc Stock (NTHI) Latest News
NeOnc Technologies Secures UAE IND Approval for NEO212, Advancing Global Phase 2 Trials for Aggressive Brain Tumors - Minichart
NeOnc Wins UAE IND Clearance for NEO212 Brain Therapy - TipRanks
NeOnc secures Abu Dhabi IND for NEO212, clears path to Phase 2 at 610 mg - TradingView
NeOnc Technologies Holdings Inc (NTHI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NeOnc Technologies Holdings Inc (NTHI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NeOnc Technologies Holdings Inc (NTHI) Institutional Confidence - TradingKey
NeOnc Technologies Holdings Inc (NTHI) Valuation: PE, PB & Fair Value Analysis - TradingKey
NeOnc Technologies Holdings Inc (NTHI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NeOnc Technologies Holdings Inc (NTHI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NeOnc's Global Expansion Accelerates After Abu Dhabi IND Approval for NEO212 - The Manila Times
NeOnc's Global Gambit: Abu Dhabi Nod Accelerates Brain Cancer Attack - BriefGlance
Top Biotech Gainers: CRVO On Watch, SLP Scooped Up, LNAI Back In Compliance, NTHI Advances NEO212 - RTTNews
NeOnc Technologies Holdings Secures IND Authorization for NEO212, Advancing Clinical Programs for Aggressive Brain Cancers - Quiver Quantitative
NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development - Stocktwits
NeOnc Technologies Says Abu Dhabi Clears NEO212 for Phase 2 Brain Cancer Trial - marketscreener.com
NeOnc receives UAE clearance for NEO212 brain cancer trial - Investing.com
NeOnc’s Brain Cancer Drug Forges Global Path Through UAE Approval - BriefGlance
NeOnc Technologies Holdings Inc (NTHI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates - TMX Newsfile
NTHI Q1 2026 Earnings: Wider-than-Expected EPS Loss Amid Pre-Revenue Phase; Stock Rises 5.56%Strong Earnings Momentum - newsline.com
NeOnc Technologies Announces New Series A Preferred Financing - TipRanks
NeOnc Technologies Announces Up To $5 Million Series A Convertible Preferred Private Placement - TradingView
NeOnc Technologies sets up $5M Series A preferred sale | NTHI 8-K Filing - Stock Titan
NeOnc (NTHI) virtual shareholder meeting Aug 14, 2026 — director elections, Plan Amendment - Stock Titan
NTHI Q1 2026 Earnings: EPS Misses as Clinical-Stage Biotech Reports Continued R&D Spend, Stock RisesPositive Surprise Momentum - lwvtexas.org
NeOnc Technologies Holdings, Inc. (NTHI) Stock Price, News, Quote & History - Yahoo! Finance Canada
The Race to Defeat Brain Cancer Could Become One of the Biggest Biotech Stories of the Decade - FinancialContent
NeOnc Technologies Initiated at Buy by Alliance Global Partners - Moomoo
NTHI Q1 2026 Earnings: Wider-than-Expected Loss Reflecting Pre-Revenue R&D StageEarnings Season Preview - newsline.com
NTHI Q1 2026 Earnings: EPS Miss Reflects Pre‑Revenue Biotech’s Rising R&D BurnNegative Surprise Momentum - newsline.com
NeOnc Shares Move Up With Key Brain Cancer Trial Updates Ahead - Bez Kabli
NeonC technologies (NTHI) president buys $153k in stock - Investing.com
NTHI Q1 2026 Earnings: Clinical-Stage Biotech Misses EPS Estimates but Stock Edges HigherConsensus Forecast Report - newsline.com
NeOnc Technologies Emerges as Top Penny Stock After Analysts Issue Buy Ratings - asatunews.co.id
Alliance Global and Maxim Initiate Coverage on NeOnc Technologies - HarianBasis.co
NeOnc Technologies (NTHI) Could Be Targeting A Challenging Market With A Different Strategy - Insider Monkey
NTHI Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Continues R&D InvestmentFinal Results - The Legal Advocate
The Next Great AI Revolution May Be Drug Delivery - GlobeNewswire
NTHI Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue StageMargin Improvement Report - newsline.com
Analysts Offer Insights on Healthcare Companies: Spectral AI (MDAI), NeOnc Technologies Holdings, Inc. (NTHI) and Innoviva (INVA) - The Globe and Mail
NTHI - Finviz
BTIG Maintains NeOnc Technologies(NTHI.US) With Buy Rating, Maintains Target Price $15 - Moomoo
NeOnc Technologies (NTHI) Slips Nearly 2% as Stock Holds Above Key SupportJurik MA - The Legal Advocate
NeOnc Technologies (NTHI) Edges Lower but Holds Above Key Support as Trading Volume Remains SubduedZero Lag EMA - The Legal Advocate
NeOnc Technologies Holds Ground Near Key Support Amid Biotech Uncertainty (NTHI)Bull Flag - The Legal Advocate
NeOnc Technologies Holdings (NTHI) Holds Near Support as Modest Decline Tests Key LevelFactor Valuation - Newser
NTHI Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Focuses on Pipeline Development - newsline.com
NTHI Initiated Coverage by Alliance Global Partners -- Rating Se - GuruFocus
NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones - The Manila Times
NeOnc Technologies Gains Analyst Favor with Growing Insider and Institutional Interest in CNS Cancer Therapies - Quiver Quantitative
Wall Street firms back brain-cancer biotech as trial data nears - Stock Titan
Neonc Technologies Holdings Inc Stock (NTHI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):